- Home
- GDEV vs SIGA Comparison
GDEV vs SIGA Comparison
Compare GDEV & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEV | SIGA |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | Cyprus | United States |
| Employees | 475 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 341.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | GDEV | SIGA |
|---|---|---|
| Price | $12.70 | $4.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.6K | ★ 439.7K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $8.05 | $224.81 |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.25 | $4.10 |
| 52 Week High | $42.20 | $9.62 |
Technical Indicators
Market Signals| Indicator | GDEV | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 35.72 | 41.87 |
| Support Level | $12.05 | $4.26 |
| Resistance Level | $18.24 | $4.84 |
| Average True Range (ATR) | 0.86 | 0.11 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 22.78 | 14.41 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.